Literature DB >> 16495512

Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism.

Jean-François Mauger1, Patrick Couture, Nathalie Bergeron, Benoît Lamarche.   

Abstract

Apolipoprotein C-III (apoC-III) production rate (PR) is strongly correlated with plasma triglyceride (TG) levels. ApoC-III exists in three different isoforms, according to the sialylation degree of the protein. We investigated the kinetics and respective role of each apoC-III isoform in modulating intravascular lipid/lipoprotein metabolism. ApoC-III kinetics were measured in a sample of 18 healthy men [mean age (+/-SD) 42.1 +/- 9.5 years, body mass index 29.8 +/- 4.6 kg/m2] using a primed-constant infusion of l-(5,5,5-D3) leucine for 12 h. Mono-sialylated and di-sialylated apoC-III (apo-CIII1 and apoC-III2) exhibited similar PRs (means +/- SD, 1.22 +/- 0.49 mg/kg/day vs. 1.15 +/- 0.59 mg/kg/day, respectively) and similar fractional catabolic rates (FCRs) (0.51 +/- 0.13 pool/day vs. 0.61 +/- 0.24 pool/day, respectively). Nonsialylated apoC-III (apoC-III0) had an 80% lower PR (0.25 +/- 0.12 mg/kg/day) and a 60% lower FCR (0.21 +/- 0.07 pool/day) (P < 0.0001 for comparison with CIII1 and CIII2 isoforms). The PRs of apoC-III1 and apoC-III2 were more strongly correlated with plasma TG levels (r > 0.8, P < 0.0001) than was apoC-III0 PR (r = 0.54, P < 0.05). Finally, the PR of apoC-III2 was strongly correlated with the proportion of LDL <255 A (r = 0.72, P = 0.002). These results suggest that all apoC-III isoforms, especially the predominant CIII1 and CIII2 isoforms, contribute to hypertriglyceridemia and that apoC-III2 may play a significant role in the expression of the small, dense LDL phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495512     DOI: 10.1194/jlr.M500455-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  17 in total

1.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

2.  Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Frank M Sacks
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

3.  Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors.

Authors:  Sophia Morel; Jade Leahy; Maryse Fournier; Benoit Lamarche; Carole Garofalo; Guy Grimard; Floriane Poulain; Edgard Delvin; Caroline Laverdière; Maja Krajinovic; Simon Drouin; Daniel Sinnett; Valérie Marcil; Emile Levy
Journal:  J Lipid Res       Date:  2017-03-08       Impact factor: 5.922

4.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

5.  Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

Authors:  Adriaan G Holleboom; Helen Karlsson; Ruei-Shiuan Lin; Thomas M Beres; Jeroen A Sierts; Daniel S Herman; Erik S G Stroes; Johannes M Aerts; John J P Kastelein; Mohammad M Motazacker; Geesje M Dallinga-Thie; Johannes H M Levels; Aeilko H Zwinderman; Jonathan G Seidman; Christine E Seidman; Stefan Ljunggren; Dirk J Lefeber; Eva Morava; Ron A Wevers; Timothy A Fritz; Lawrence A Tabak; Mats Lindahl; G Kees Hovingh; Jan Albert Kuivenhoven
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

6.  Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells.

Authors:  V De Re; M P Simula; L Caggiari; N Orzes; M Spina; A Da ponte; L De Appollonia; R Dolcetti; V Canzonieri; R Cannizzaro
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

7.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

8.  Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.

Authors:  Juraj Koska; Hussein Yassine; Olgica Trenchevska; Shripad Sinari; Dawn C Schwenke; Frances T Yen; Dean Billheimer; Randall W Nelson; Dobrin Nedelkov; Peter D Reaven
Journal:  J Lipid Res       Date:  2016-03-03       Impact factor: 5.922

9.  Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population.

Authors:  Tong-Hong Niu; Man Jiang; Yong-Ning Xin; Xiang-Jun Jiang; Zhong-Hua Lin; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.